ABBV vs MRVL: Which Is the Better Buy?
Side-by-side comparison of AbbVie Inc. and Marvell Technology, Inc. — fair value, conviction, valuation metrics, and QuantHub research signals.
Updated 2026-07-06.
AbbVie Inc. · Healthcare
$261.07
+1.2% upside to fair value
Grade C
High Quality
VS
Marvell Technology, Inc. · Technology
$310.58
-18.5% upside to fair value
Grade D
QuantHub Verdict
ABBV has more upside to fair value
(+1.2%).
MRVL trades at a lower forward P/E
(105.7x).
These are model outputs — not personalized investment advice.
See all research →
Valuation & Fundamentals
| Metric |
ABBV |
MRVL |
| Current Price |
$261.07 |
$310.58 |
| Fair Value Estimate |
$264.30 |
$253.23 |
| Upside to Fair Value |
+1.2%
|
-18.5%
|
| Market Cap |
$461.3B |
$271.7B |
| Forward P/E |
128.0x
|
105.7x
|
| EV / EBITDA |
31.0x
|
59.1x
|
| Price / Sales |
7.3x
|
31.2x
|
| Price / FCF |
22.1x
|
163.2x
|
| Revenue Growth YoY |
+12.4%
|
+27.6%
|
| Gross Margin |
70.7%
|
50.6%
|
| Operating Margin |
27.6%
|
16.2%
|
| Return on Equity |
68.0%
|
16.8%
|
| Dividend Yield |
0% |
0% |
| FCF Yield |
4.52%
|
0.61%
|
| Analyst Consensus |
Strong Buy
|
Strong Buy
|
Investment Thesis
AbbVie Inc. is a leading healthcare company specializing in drug manufacturing with a strong focus on immunology and aesthetics. The company is transitioning from its historical Humira dominance, which has faced loss of exclusivity, toward high-growth assets like Skyrizi and Rinvoq that are driving robust revenue growth of 12.4% in the most recent quarter. Despite strong revenue growth and a dura…
Marvell Technology, Inc. designs and supplies semiconductor solutions primarily focused on data infrastructure markets including cloud, AI, carrier 5G, and custom silicon. The company benefits from a narrow but widening moat driven by strong IP and hyperscaler relationships, led by an experienced CEO with a track record of transformational M&A. Despite strong revenue growth of 42% year-over-year …
Accumulation Zones
| Metric |
ABBV |
MRVL |
| Zone Low |
$198.23 |
$189.92 |
| Zone High |
$224.66 |
$215.25 |
| In Buy Zone? |
No
|
No
|